Our Lesson From an Overblown Housing 'Boogeyman'

There will always be a reason not to buy stocks. And focusing on fear-inducing headlines will almost always lead to bad investing decisions. Today, we'll discuss why you shouldn't let the next "boogeyman" headline dictate your portfolio decisions... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] Our Lesson From an Overblown Housing 'Boogeyman' By Chris Igou, analyst, True Wealth --------------------------------------------------------------- This is one of the quickest ways to ruin your portfolio... I don't care if you are a market veteran or a newbie. You need to understand this idea. Fortunately, it's simple... Don't let the next "boogeyman" headline dictate your portfolio decisions. There will always be a reason not to buy stocks. And focusing on fear-inducing headlines will almost always lead to bad investing decisions. You see, the financial media will do its best to make the next boogeyman as scary as possible. And it will seem like you have to act right away to save your money... But that's almost never the case. This happened recently in the housing market. And as I'll share today, it was a boogeyman you were smart to ignore. Let me explain... --------------------------------------------------------------- Recommended Links: [Nervous? I'm not!]( When the Dow fell nearly 2,000 points after Thanksgiving, I didn't flinch. It's not that I've quit investing... or that I'm willing to settle for inferior returns. No way. It's just that I found a way to get OFF the stock market roller coaster for good. It's all thanks to ONE investing idea – one that I've used to make legally protected gains as high as 658% WITHOUT stocks or options. [I explain everything right here](. --------------------------------------------------------------- [NEW: No. 1 Biotech Stock to Own in 2022]( According to expert Dave Lashmet, the biggest breakthrough of the decade has nothing to do with flying cars, 5G, the Internet of Things, or artificial intelligence. Instead, it's within a new medical market bigger than oncology, diabetes, strokes, kidney disease, and heart disease... COMBINED. And there's just one company and its little-known pill at the center of it all. [Get the critical details right here](. --------------------------------------------------------------- The housing market has been booming since the pandemic began nearly two years ago. And that has investors wondering what will kill this bull market. A recent concern was the end of the eviction moratorium the U.S. government originally put into place in September 2020. The goal of the moratorium was to protect renters who were being hurt by the pandemic. And when that aid was set to expire this past summer, the headlines pounced on investors' fears... Before long, the media was saying the return of evictions would kick off the next housing crisis. Here's a headline from CNBC back in May... It wasn't just CNBC running headlines like these... Boogeyman stories about the housing market were popping up all over the place. And the fear got worse. Just look at this July headline from the Economist... A "wave of foreclosures" would be bad news for the housing market. It would mean a boost in supply. It could hurt both prices and overall demand. It's a perfect example of what a boogeyman looks like for investors. First, it affects a wide range of people. Second, it invokes fear of a market crash coming on the heels of foreclosures. And most important, you don't have much time to prepare for it... Bailing on the housing market in the summer wouldn't have been a smart move, though. The eviction moratorium ended in August... But we haven't seen anything like what the media headlines were calling for. Houses aren't foreclosing at a large scale. In fact, home sales in the U.S. are still high. Market supply is still near zero, and demand continues to rage. One of our favorite ways to gauge the strength of the housing market is to look at the total months of existing home supply. It shows how quickly we could sell all of the existing homes on the market. When supply is vast, it takes longer to get rid of existing inventory. And when inventory is tight, buyers snap up homes quickly. Today, it would take a little more than two months to sell all existing homes based on investor demand. That's near the lowest supply on record. And it's darn bullish for the housing market. This is certainly not the takeaway you would have gleaned from reading the media's boogeyman headlines... Four months have passed since the eviction moratorium expired... Yet, the housing boom is still in full swing. Homebuilder stocks are up another 8% since the end of August. And they are up 19% since their September bottom. Simply put, this housing boogeyman didn't kill the boom. And that's an important lesson for investors. There's always going to be a boogeyman to worry about. But that doesn't mean you should let your fears drive your portfolio decisions. Instead, focus on the facts – and only take action when they change. Good investing, Chris Igou Further Reading The pandemic upended almost every aspect of our lives. And with many of those issues still lingering, homeowners found themselves falling behind on their payments. While it seems like this could topple the real estate market, we don't expect the housing boom to end anytime soon... [Read more here](. "When it comes to housing, it's always about supply and demand," Steve writes. The supply imbalance in the housing market today means home prices can rocket even higher... [Get the full story here](. INSIDE TODAY'S DailyWealth Premium A housing company to own even if interest rates rise... The housing boom has plenty of room to run. And one company is capturing the upside in housing in a unique way... [Click here to get immediate access](. Market Notes HIGHS AND LOWS NEW HIGHS OF NOTE LAST WEEK AbbVie (ABBV)... [pharmaceuticals]( CVS Health (CVS)... drugstores Thermo Fisher Scientific (TMO)... life sciences Quest Diagnostics (DGX)... [medical data]( Digital Realty Trust (DLR)... data-center REIT Life Storage (LSI)... self-storage REIT Extra Space Storage (EXR)... self-storage REIT Church & Dwight (CHD)... [household products]( Procter & Gamble (PG)... [consumer goods]( McDonald's (MCD)... burgers and fries Coca-Cola (KO)... [soft drinks]( General Mills (GIS)... [food products]( Hershey (HSY)... ["Global Elite" chocolatier]( Nestlé (NSRGY)... [snacks and candy]( Costco Wholesale (COST)... [membership-only stores]( AutoZone (AZO)... auto parts NEW LOWS OF NOTE LAST WEEK Southwest Airlines (LUV)... airline Medtronic (MDT)... medical technology Annaly Capital Management (NLY)... "virtual bank" --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers’ feedback. To help us improve your experience, we’d like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberrycustomerservice.com. Please note: The law prohibits us from giving personalized investment advice. © 2021 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [www.stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.